Current FDA Approval Status for Lurbinectedin
Lurbinectedin (brand name Zepzelca) received accelerated FDA approval on June 15, 2020, for adults with metastatic small cell lung cancer (SCLC) that progressed on or after platinum-based chemotherapy.[1] Full approval requires confirmatory trial data, with the ongoing LAGOON trial (NCT04676832) evaluating it in combination with doxorubicin as a second-line treatment.
When Might Full Approval Happen?
The FDA set a PDUFA target action date of August 4, 2024, for potential conversion to full approval based on LAGOON interim results submitted by Jazz Pharmaceuticals in late 2023.[2] However, the agency issued a Complete Response Letter (CRL) on August 2, 2024, citing issues with a third-party manufacturing vendor rather than efficacy or safety concerns. Jazz resubmitted the application on September 20, 2024, triggering a six-month review clock under accelerated approval rules.[3]
What Delays Full Approval?
The CRL focused on Chemistry, Manufacturing, and Controls (CMC) compliance at a contract manufacturer, not clinical data. Jazz addressed this in the resubmission, but FDA audits or additional inspections could extend the timeline. Analysts expect a decision by March 2025, though no new PDUFA date is confirmed yet.[4] Accelerated approval remains intact during review.
Approval Timelines in Europe and Elsewhere
The European Commission granted conditional approval in August 2021 for the same SCLC indication.[5] Japan's PMDA approved it in September 2022. No major global expansions are pending beyond potential label updates.
Impact on Access and Pricing
Zepzelca launched at $13,000–$18,000 per cycle in the US, covered by most insurers for approved uses. Full approval could expand reimbursement and enable combinations, but biosimilar competition is years away due to orphan drug exclusivity until 2027.[6]
Ongoing Trials and Future Indications
Phase 3 trials like IMforte (NCT04702737) test lurbinectedin with atezolizumab in extensive-stage SCLC, with data readouts possible in 2025–2026. These could support frontline approval.[7]
[1]: FDA Approval Announcement
[2]: Jazz Pharmaceuticals Press Release, Dec 2023
[3]: Jazz Q3 2024 Earnings
[4]: Evaluate Pharma Analysis
[5]: EMA Approval
[6]: DrugPatentWatch.com - Zepzelca Exclusivity
[7]: ClinicalTrials.gov - IMforte